CPD Courses

6.5-year data from CheckMate 067 Long-term outcomes and safety

Online Course Bristol Myers Squibb

About the CPD course

This module will guide you through the key data and safety results from the 6.5-year analysis of Phase III study CheckMate 067. Throughout; you will be given some points about the current treatment pathway to consider. At the end of the module.

CPD Provider

Bristol Myers Squibb

Bristol Myers Squibb

Bristol Myers Squibb

We are a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are focused on helping millions of patients around the world in disease areas such as oncology, haematology, cardiology, immunology, fibrosis, and specialty medicines. Through our Research & Development organisation, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.

Want to learn more?

Contact us

More CPD courses by Bristol Myers Squibb

Healthcare & Medical

OPDIVO (nivolumab) + YERVOY (ipilimumab):Understan...

Bristol Myers Squibb

This module will guide you through the mechanism of action for the combination of OPDIVO (nivolumab)...
Online Course
Healthcare & Medical

Positive outcomes for multiple patient types: 6.5-...

Bristol Myers Squibb

This module will guide you through the key subgroup data from the 6.5-year analysis of the Phase III...
Literature

Get industry-related content straight to your inbox

By signing up to our site you are agreeing to our privacy policy